a therapeutics company focusing on discovering and developing novel gene control therapies
Industry Biotechnology
A.I.dvisor indicates that over the last year, SYRS has been loosely correlated with XFOR. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRS jumps, then XFOR could also see price increases.
Ticker / NAME | Correlation To SYRS | 1D Price Change % | ||
---|---|---|---|---|
SYRS | 100% | -86.85% | ||
XFOR - SYRS | 56% Loosely correlated | -53.17% | ||
CTXR - SYRS | 35% Loosely correlated | -20.01% | ||
CGEN - SYRS | 30% Poorly correlated | -0.62% | ||
SVRA - SYRS | 29% Poorly correlated | -15.14% | ||
ATXS - SYRS | 28% Poorly correlated | -4.93% | ||
More |
Ticker / NAME | Correlation To SYRS | 1D Price Change % |
---|---|---|
SYRS | 100% | -86.85% |
cancer theme (82 stocks) | 14% Poorly correlated | -2.38% |
stem cells theme (21 stocks) | 13% Poorly correlated | -3.58% |
plastic surgery theme (5 stocks) | 13% Poorly correlated | -7.19% |
drugs theme (254 stocks) | 12% Poorly correlated | -1.72% |
biotechnology theme (238 stocks) | 8% Poorly correlated | -1.80% |